European approval for stroke therapy

Israel’s Brain.Q (see here previously) has received the CE-Mark for its BQ 2.0 system, designed to reduce disability following ischemic stroke, the number one cause of disability worldwide. Brain.Q is also enrolling in the EMAGINE II pivotal study to seek US-FDA clearance.

https://www.ourcrowd.com/startup-news/brain-q-achieves-ce-mark-for-its-breakthrough-therapy-for-reducing-disability-following-stroke-and-welcomes-stacey-pugh-as-chairman-of-the-board

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *